Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07828522) titled 'F182112 in Combination With Isatuximab and Lenalidomide for the Treatment of Patients With Newly Diagnosed Multiple Myeloma' on Sept. 15.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Condition:
Multiple Myeloma (MM)
Transplant-eligible Patients
Intervention:
Drug: F182112 Plus Isatuximab and Lenalidomide
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: October 1, 2026
Target Sample Size: 10 ...